ArticleYonsei medical journal2025
Trajectories of Alzheimer's Disease Prevalence among National Health Insurance and Medical Aid Beneficiaries from 2010 to 2019.
Article in Yonsei medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlzheimer's disease (AD) is the leading cause of dementia and is associated with various socioeconomic factors. This study aimed to ascertain the differences in AD prevalence based on healthcare coverage type as a proxy of socioeconomic status in South Korea. MATERIALS AND
methodsWe examined Health Insurance Review and Assessment Service claims from 2010-2019, identifying AD as the main disease. Crude prevalence rate and age- and sex-standardized prevalence were estimated from healthcare utilization data. Subgroup analysis by age, sex, comorbidities (hypertension, diabetes, and cardiovascular disease), and type of healthcare coverage [Medical Aid (MA) vs. National Health Insurance (NHI)] was performed to estimate the standardized prevalence rate ratio (PRR).
resultsAD prevalence increased 3.9 times from 2010 (175688 cases) to 2019 (680800 cases). In the NHI group, the standardized prevalence increased 2.3-fold (624.4 in 2010 and 1433.2 in 2019), whereas the MA group saw a 2.7-fold increase (1251.0 in 2010 and 3391.9 in 2019). AD was significantly higher in the MA group from 2010 [PRR=2.00, 95% confidence interval (CI) 1.98-2.03] to 2019 (PRR=2.37, 95% CI 2.35-2.38) compared to the NHI group. From 2010 to 2019, a proportion of comorbidities increased in MA and NHI groups. Compared to the NHI group, the MA group showed significantly higher proportion of comorbidities.
conclusionIn this study, we identified significant differences in AD prevalence between NHI and MA recipients, with a notable increase in the MA group, especially among those under 60 years of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.